Advertisement
ALGN vs IDXX
Which Stock Would AI Choose? Align Technology (ALGN) vs. IDEXX Laboratories (IDXX) Stock Comparison
Key Takeaways
- Align Technology (ALGN) has delivered positive year-to-date returns of approximately 13%, while IDEXX Laboratories (IDXX) has declined roughly 16% over the same period.
- Both companies operate in the healthcare sector but serve fundamentally different end markets: ALGN targets consumer-driven orthodontics, while IDXX focuses on non-discretionary veterinary diagnostics.
- IDXX commands a substantially larger market capitalization (~$44.8 billion vs. ~$12.7 billion) and superior profitability metrics, including a net margin above 24%.
- ALGN is actively pursuing growth through international expansion, new product launches, and a $200 million share buyback program, while IDXX faces pressure from analyst price target revisions downward.
- Both stocks carry Moderate Buy consensus ratings from Wall Street analysts, though ALGN has shown stronger price momentum in recent months.
- Investors weighing these two names must consider the trade-off between IDXX's defensive, recurring-revenue model and ALGN's higher-growth but more cyclical consumer exposure.
Introduction
Align Technology and IDEXX Laboratories represent two distinct investment propositions within the broader healthcare landscape. While both are Nasdaq-listed, innovation-driven companies with global reach, their underlying businesses cater to markedly different demand drivers. ALGN, best known for its Invisalign clear aligner system, thrives when consumer confidence is high and discretionary spending on aesthetic treatments is robust. IDXX, by contrast, provides essential diagnostic products and services for the animal health industry, a sector characterized by steady, non-cyclical demand. This comparison is relevant for investors seeking to understand how a consumer-exposed healthcare growth stock stacks up against a defensive, recurring-revenue compounder in the current market environment.
ALGN Overview and Recent Performance
Align Technology, headquartered in Tempe, Arizona, is the global leader in clear aligner orthodontics through its Invisalign system, complemented by iTero intraoral scanners and exocad CAD/CAM (Computer-Aided Design/Computer-Aided Manufacturing) software for digital dentistry. The company has treated approximately 22.8 million patients over nearly three decades and serves roughly 299,500 doctor customers worldwide. In recent weeks, ALGN shares have traded around the $175 level, reflecting a year-to-date gain of roughly 13% but a one-year decline of approximately 8%. The stock currently sits below its 52-week high of $208.30 and above its low of $122.00.
Recent market activity has been shaped by several notable developments. The company reported record first-quarter 2026 Invisalign shipments of 685,700 units, up 6.7% year-over-year, with double-digit growth across EMEA (Europe, Middle East, and Africa), APAC (Asia-Pacific), and LATAM (Latin America) regions, while North America remained approximately flat. ALGN also announced a $200 million open market share repurchase program in early May and underwent a board leadership transition, with Kevin Conroy succeeding C. Raymond Larkin, Jr. as Chairman effective July 1, 2026. The company has been highlighting its AI-powered digital dentistry platform, direct fabrication technology, and new products such as the Invisalign Palatal Expander. Its Q2 2026 earnings are scheduled for release on July 29. Wall Street analysts maintain a Moderate Buy consensus with an average price target near $206.
IDXX Overview and Recent Performance
IDEXX Laboratories, based in Westbrook, Maine, is a global leader in veterinary diagnostics, providing in-clinic analyzers, rapid assay test kits, reference laboratory services, and practice-management software primarily for companion animals, as well as water quality and livestock testing. The company serves veterinarians, dairy and livestock producers, and utilities across more than 175 countries. IDXX shares have recently traded near $564, reflecting a year-to-date decline of approximately 16% amid broader market rotation away from higher-valuation healthcare names, though the one-year return remains positive at roughly 9%.
IDXX delivered solid first-quarter 2026 results, posting earnings per share (EPS) of $3.47 on revenue of $1.14 billion, both modestly exceeding consensus estimates. Revenue grew 14.3% compared to the same quarter a year earlier, underscoring resilient demand for animal health diagnostics. The company maintains exceptional profitability, with a net margin of 24.63% and return on equity (ROE) of roughly 71%. However, sentiment has been tempered by several analyst price target reductions in recent months — UBS lowered its target from $730 to $640, Stifel from $775 to $675, and Citigroup initiated coverage with a Neutral rating and a $650 target. The consensus analyst rating remains Moderate Buy, with an average target of $751, implying significant upside from current levels. IDXX's next earnings report is anticipated in early August.
Trending AI Robots
For traders seeking a data-driven edge in navigating comparisons like ALGN versus IDXX, Tickeron's Trending AI Robots page offers access to a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each employing distinct trading styles, strategies, and timeframes. Only the bots that demonstrate the strongest alignment with current market conditions earn a place in the Trending AI Robots section. This curated list is designed to help users identify algorithmic strategies with proven adaptability and performance in real-time environments, with bots showcasing metrics such as annualized returns and trade accuracy rates that can range meaningfully depending on the strategy employed. Exploring this page can offer a practical window into how artificial intelligence interprets evolving market dynamics across stocks like ALGN and IDXX. Visit the Trending AI Robots page to discover which algorithms are currently leading the pack.
Head-to-Head Comparison
From a business model perspective, ALGN and IDXX occupy sharply different positions. ALGN's revenue depends heavily on consumer willingness to pay out-of-pocket for elective orthodontic treatment — a dynamic that ties the company's fortunes to consumer confidence, employment trends, and discretionary income. IDXX, conversely, generates most of its revenue from diagnostic testing that veterinarians rely on regardless of economic conditions; pet owners generally do not forgo blood work or urinalysis for a sick animal, making IDXX's revenue stream notably more defensive.
On growth drivers, ALGN is pushing multiple levers simultaneously: expanding into underpenetrated international markets such as India, Turkey, and Southeast Asia; launching new products like the 3D-printed Invisalign Palatal Expander and Vivera retainers; scaling direct fabrication to reduce manufacturing costs; and deploying AI-driven treatment planning to shorten case turnaround times. IDXX's growth is more organically tied to rising pet ownership, increased spending per pet, and expanding placement of its in-clinic diagnostic instruments globally.
From a valuation and momentum standpoint, ALGN trades at a P/E (Price-to-Earnings) ratio of approximately 30, significantly below IDXX's multiple of roughly 42, reflecting the market's willingness to pay a premium for IDXX's more predictable earnings stream. However, ALGN has demonstrated stronger recent price momentum, with its 50-day moving average trending upward. IDXX, by contrast, trades below its 200-day moving average of approximately $599, indicating lingering technical pressure. Risk factors diverge meaningfully: ALGN faces headwinds from consumer spending softness in North America and competition from lower-cost clear aligner alternatives, while IDXX's primary risks include valuation compression in a higher-rate environment and potential slowdowns in clinic visit volumes.
Tickeron AI Verdict
Based on observable trend dynamics, relative positioning, and catalyst profiles, Tickeron's AI analytical framework would likely exhibit a modest near-term preference for ALGN over IDXX at the current juncture. Several factors support this probabilistic tilt: ALGN's positive year-to-date momentum contrasts with IDXX's negative trajectory; the stock's lower absolute valuation multiple may offer more room for multiple expansion; and the company has a concentrated set of identifiable catalysts — including the upcoming Q2 earnings report, international expansion milestones, and the active share buyback program. IDXX remains a fundamentally stronger business by most profitability metrics and offers a more durable earnings base, but the current technical configuration and the pattern of downward analyst revisions suggest near-term uncertainty. As always, this assessment reflects a probabilistic, data-driven perspective rather than a definitive prediction, and market conditions can shift rapidly in either direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Hold and IDXX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 0 FA rating(s) are green whileIDXX’s FA Score has 1 green FA rating(s).
- ALGN’s FA Score: 0 green, 5 red.
- IDXX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 4 TA indicator(s) are bullish while IDXX’s TA Score has 4 bullish TA indicator(s).
- ALGN’s TA Score: 4 bullish, 4 bearish.
- IDXX’s TA Score: 4 bullish, 5 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а -4.00% price change this week, while IDXX (@Medical Specialties) price change was -1.35% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.40%. For the same industry, the average monthly price growth was -0.68%, and the average quarterly price growth was -3.63%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.36%. For the same industry, the average monthly price growth was -0.23%, and the average quarterly price growth was +7.35%.
Reported Earning Dates
ALGN is expected to report earnings on Jul 29, 2026.
IDXX is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+1.40% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-0.36% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ALGN | IDXX | ALGN / IDXX | |
| Capitalization | 12B | 43.9B | 27% |
| EBITDA | 877M | 1.56B | 56% |
| Gain YTD | 7.621 | -17.786 | -43% |
| P/E Ratio | 28.24 | 40.93 | 69% |
| Revenue | 4.1B | 4.45B | 92% |
| Total Cash | 1.06B | 201M | 527% |
| Total Debt | 116M | 1.11B | 10% |
ALGN | IDXX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 67 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 16 | |
PRICE GROWTH RATING 1..100 | 60 | 59 | |
P/E GROWTH RATING 1..100 | 77 | 75 | |
SEASONALITY SCORE 1..100 | 50 | 31 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (68) in the Medical Specialties industry is in the same range as IDXX (80). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IDXX (100). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for ALGN (69). This means that IDXX’s stock grew somewhat faster than ALGN’s over the last 12 months.
IDXX's Price Growth Rating (59) in the Medical Specialties industry is in the same range as ALGN (60). This means that IDXX’s stock grew similarly to ALGN’s over the last 12 months.
IDXX's P/E Growth Rating (75) in the Medical Specialties industry is in the same range as ALGN (77). This means that IDXX’s stock grew similarly to ALGN’s over the last 12 months.
| ALGN | IDXX | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 66% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 72% | 2 days ago 71% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 53% |
| Advances ODDS (%) | 16 days ago 70% | 2 days ago 58% |
| Declines ODDS (%) | 5 days ago 74% | 6 days ago 70% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 75% | 2 days ago 77% |
Advertisement
IDXX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | +2.18% | ||
| ALGN - IDXX | 50% Loosely correlated | +0.62% | ||
| SYK - IDXX | 48% Loosely correlated | +1.97% | ||
| BLCO - IDXX | 45% Loosely correlated | +0.68% | ||
| SNN - IDXX | 44% Loosely correlated | +1.80% | ||
| STE - IDXX | 40% Loosely correlated | +2.02% | ||
More | ||||